New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 19, 2013
09:03 EDTASTMAastrom announces first patients treated in ixCELL-DCM clinical study of ixmyelocel-T
Aastrom Biosciences announced that the first patients were treated in the ixCELL-DCM Phase 2b clinical trial. This study is evaluating the safety and efficacy of ixmyelocel-T compared to placebo in patients with advanced heart failure due to ischemic dilated cardiomyopathy. Aastrom has received U.S. orphan drug designation for the use of ixmyelocel-T in patients with DCM.
News For ASTM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
17:23 EDTASTMAastrom changes name to Vericel
Aastrom Biosciences (ASTM) announced the change of its corporate name to Vericel (VCEL), effective immediately. The name change has been approved by the company's shareholders. In conjunction with this change, the company has moved its headquarters to Cambridge, Massachusetts, site of its commercial manufacturing facility. Vericel also will maintain operations and several key corporate functions in Ann Arbor, Michigan. he company's common stock will begin trading tomorrow, November 25, at market open on the NASDAQ Capital Market under its new stock ticker symbol "VCEL". The new CUSIP number for the company's common stock is 92346J108 following the name and ticker change.
November 13, 2014
08:19 EDTASTMAastrom reports Q3 EPS (82c), consensus (66c)
Reports Q3 revenue $9.65M, consensus $6.73M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use